Q4 2025 Adjusted EBITDA was $281 million, compared to Adjusted EBITDA of $16 million in Q4 2024 -- Q4 2025 net income attributable to IEP was $1 million, compared to a net loss of $98 million in Q4 ...
Which Is a Better Investment, Apellis Pharmaceuticals, Inc. or Protagonist Therapeutics, Inc. Stock?
Learn more about whether Apellis Pharmaceuticals, Inc. or Protagonist Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
This interview took place on Feb. 16, 2026, and the full transcript below has been lightly edited for clarity.
New York City’s complex property tax system affects everyone in the city, not just people who own property. The cost of those taxes affects retail space, how much you pay for rent and how (and where) ...
The White House is stepping up efforts to implement President Donald Trump‘s proposed ban on investors buying homes. A memo ...
Please note that the limited information that follows in this press release is a summary and is not adequate for making ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results